Clinical Trials for Small Cell Lung Cancer

Phase II Trial of Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial targets patients with Stage IV NSCLC who have high-risk thoracic lesions and lack targetable mutations such as EGFR or ALK, evaluating the efficacy of prophylactic palliative thoracic radiotherapy in combination with standard systemic therapies like chemotherapy or immunotherapy to prevent symptomatic progression in the thorax.

ClinicalTrials.gov ID: NCT06262321

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This study enrolls patients with incurable locally advanced or metastatic epithelial solid tumors, particularly NSCLC, who have measurable disease and ECOG performance status 0–1. Patients receive intravenous BL-B01D1 (izalontamab brengitecan), an investigational EGFR/HER3-targeting bispecific antibody–drug conjugate that delivers a topoisomerase I inhibitor, on one of two 21-day dosing schedules.

ClinicalTrials.gov ID: NCT05983432

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, progressing ovarian or endometrial cancer are the main population; dose-escalation cohorts also include metastatic triple-negative breast cancer and non-small-cell lung adenocarcinoma. Patients receive intravenous farletuzumab ecteribulin (MORAb-202), an investigational FRα-targeting antibody–drug conjugate that delivers eribulin; one cohort also receives short-course corticosteroids to assess whether they reduce ILD.

ClinicalTrials.gov ID: NCT04300556

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: The trial involves treatment-naïve adults with metastatic non-small cell lung cancer featuring actionable driver mutations, using radiation therapy on the primary lung lesion followed by tyrosine kinase inhibitor (TKI) therapy to delay disease progression. Radiation doses range from 24-60 Gy, and TKI treatment targets genetic mutations driving cancer growth.

ClinicalTrials.gov ID: NCT06305715

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated advanced solid tumors and ECOG 0–1 are eligible for genotype-defined cohorts with KRAS, NRAS, or HRAS mutations; a separate cohort includes RAS–wild-type pancreatic ductal adenocarcinoma. All patients receive oral daraxonrasib (RMC-6236), a multiselective RAS(ON) inhibitor that blocks signaling by active RAS.

ClinicalTrials.gov ID: NCT05379985

A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 As a Single Agent and in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients with Advanced or Metastatic Solid Tumors (Keynote B59)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive GI-101 or GI-101A alone or in combination with pembrolizumab; GI-101 may also be combined with lenvatinib or local radiotherapy. GI-101 is a CD80–IL-2-variant fusion protein designed to counter CTLA-4-mediated suppression and stimulate cytotoxic T and natural-killer cells; GI-101A is a manufacturing-optimized formulation.

ClinicalTrials.gov ID: NCT04977453

A Phase 2 Study of First-line Sotorasib for Patients with Advanced KRAS G12C-mutant Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial involves adult patients with advanced KRAS G12C-mutant NSCLC, focusing on assessing the safety and efficacy of the KRAS G12C inhibitor sotorasib as a first-line treatment. Participants must have a KPS of 70% or greater, measurable disease, no prior therapy in the advanced setting, and meet specific organ function and biopsy consent criteria.

ClinicalTrials.gov ID: NCT06582771

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors, including renal, prostate, urothelial, liver, lung, colorectal, and head and neck cancers, receive oral zanzalintinib alone or with nivolumab, nivolumab plus ipilimumab, or nivolumab plus relatlimab. Zanzalintinib inhibits VEGFR2, MET, and TAM kinases; the checkpoint inhibitors target PD-1, CTLA-4, and LAG-3, respectively.

ClinicalTrials.gov ID: NCT05176483

A Multi-Center Phase 2 Study of Hippocampal Avoidance in Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial targets adults with breast cancer or NSCLC with leptomeningeal metastases, using craniospinal irradiation with hippocampal avoidance via proton or VMAT to reduce neurological side effects while effectively treating the cancer. Participants require a KPS of ≥ 60 and suitable blood counts, and treatment is given over two weeks.

ClinicalTrials.gov ID: NCT06518057

Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial involves patients with stage IV PD-L1 positive NSCLC that progressed after at least two doses of anti-PD-1/PD-L1 therapy, excluding specific cancer subtypes, and explores the efficacy and safety of combining healthy donor fecal microbiota transplants (hdFMT) with pembrolizumab, a PD-1 inhibitor.

ClinicalTrials.gov ID: NCT05669846